Research ArticlePROCEEDINGS OF THE 23RD ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES

Mutant KRAS Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion

KENSUKE NISHI, SHUHEI ISHIKURA, MASAYO UMEBAYASHI, TAKASHI MORISAKI, TAKASHI INOZUME, TETSUSHI KINUGASA, MIKIKO AOKI, SATOSHI NIMURA, ANTHONY SWAIN, YOICHIRO YOSHIDA, SUGURU HASEGAWA, KAZUKI NABESHIMA, TOSHIFUMI SAKATA, SENJI SHIRASAWA and TOSHIYUKI TSUNODA
Anticancer Research August 2020, 40 (8) 4663-4674; DOI: https://doi.org/10.21873/anticanres.14465

Abstract

Background/Aim: Roles for mutant (mt) KRAS in the innate immune microenvironment in colorectal cancer (CRC) were explored. Materials and Methods: Human CRC HCT116-derived, mtKRAS-disrupted (HKe3) cells that express exogenous mtKRAS and allogenic cytokine-activated killer (CAK) cells were co-cultured in 3D floating (3DF) culture. The anti-CD155 antibody was used for function blocking and immuno histochemistry. Results: Infiltration of CAK cells, including NKG2D+ T cells, into the deep layer of HKe3-mtKRAS spheroids, was observed. Surface expression of CD155 was found to be up-regulated by mtKRAS in 3DF culture and CRC tissues. Further, the number of CD3+ tumor-infiltrating cells in the invasion front that show substantial CD155 expression was significantly larger than the number showing weak expression in CRC tissues with mtKRAS. CD155 blockade decreased the growth of spheroids directly and indirectly through the release of CAK cells. Conclusion: CD155 blockade may be useful for therapies targeting tumors containing mtKRAS.

Mutation in the Kirsten rat sarcoma viral oncogene homolog (KRAS) is present in various human cancers and is associated with poor prognosis (1, 2). KRAS mutations are found in 30%-40% of colorectal cancers (CRCs) (2, 3). Extensive effort has been put toward the development of chemical compounds that directly target and inhibit constitutively active KRAS (4). However, such drugs have not yet reached clinical use (5).

Cancer immunotherapy has recently achieved significant progress. The application of monoclonal antibodies targeting cytotoxic T lymphocyte (CTL)-associated antigen 4 (CTLA-4) or programmed death receptor-1 (PD-1) has promoted adaptive antitumor activity through blockade of inhibitory receptor–ligand interactions, with remarkable clinical benefits (6). Recently, the US Food and Drug Administration approved PD-1 blockade for metastatic CRC that displays mismatch repair (MMR) deficiency (7). MMR deficiency produces a large proportion of passenger mutations and subsequent transcription of neoantigens (8). T cells recognize neoantigens via T cell receptor–MHC class I interactions and become sensitive to immune checkpoint blockade associated with PD-1–PD-L1 interaction (9). However, CRC cells frequently escape T cell-mediated control by down-regulating the expression of MHC class I receptors (10, 11). Previous investigations demonstrate that other tumors with KRAS mutations, such as mutant (mt) KRAS pancreatic ductal adenocarcinomas, are resistant to checkpoint immunotherapies (12). Furthermore, mtKRAS down-regulates MHC class I receptors during metastasis of non-small cell lung cancer (13), suggesting that blockade of this immune checkpoint is ineffective for cancers expressing mtKRAS.

The activation of innate immune cells, including natural killer T (NKT) and (NK) cells, is currently considered a promising therapeutic approach for the treatment of various types of cancer because these cells are effective killers of cancer cells without the need for prior sensitization. This ability contrasts sharply the activation of adaptive immune cells (14, 15). Numerous studies demonstrate that functional deficiencies in NK cells are associated with an increased risk of developing various cancers (12, 16, 17). Based on this information, cytokine-activated killer (CAK) cells composed of natural killer group 2, member D (NKG2D)-positive T cells (TNK cells) have previously been shown to induce cytotoxicity against various cancers in a manner independent of MHC class I (18, 19). The signaling balance between NK-activating receptors and inhibitory receptors determines the antitumor activity of CAK cells. Activating receptors include molecules such as DNAX Accessory Molecule-1 (DNAM-1) and NKG2D. Inhibitory receptors include T cell immunoreceptor with immunoglobulin, immunoreceptor tyrosine-based inhibitory motif domains (TIGIT), and PD-1 (20). For example, NKG2D recognizes its ligands, the UL16 binding proteins (ULBP) and MHC class I chain-related (MIC) protein, on cancer cells and is also thought to play an important role in mediating the activation of anticancer immune responses (21). In contrast, TIGIT contributes to immunotolerance by inhibiting immune responses mediated by T and NK cells through binding to its ligand on cancer cells (22). TIGIT competes with DNAM-1 for binding to their common ligands, including CD155 and CD112 (23-25). Several mechanisms of transcriptional/proteasomal regulation of immune-activating and inhibitory molecules on cancer cells, such as ULBP, MIC, CD155, and PD-L1, have been reported (26-28). However, the regulatory mechanisms of mtKRAS on the expression of immune-related molecules in tumor-immune microenvironments remain still unclear (29).

Recently, a 3D floating (3DF) culture system was established using human CRC HCT116-derived mtKRAS-disrupted cells (HKe3) that stably overexpress wild-type (wt) KRAS (HKe3-wtKRAS) or mtKRAS (HKe3-mtKRAS) (30, 31). HKe3-wtKRAS and HKe3-mtKRAS cells share the same genetic background except for mtKRAS, thereby facilitating accurate identification of molecules directly controlled by mtKRAS (30). Further, 3DF culture and co-culture are effective methods for observation of sphere formation and direct infiltration of immune cells into tumor spheroids (32). Thus, the combination of HKe3 and CAK cells in 3DF co-culture is a suitable in vitro model for analyzing the role of mtKRAS in the tumor-immune microenvironment.

mtKRAS was found to regulate the infiltration of CAK cells into tumors, and surface expression of CD155 was increased in HKe3-mtKRAS spheroids and in CRC tissues with mtKRAS. The latter finding suggests that mtKRAS up-regulates surface expression of CD155.

Materials and Methods

Antibodies and reagents. Anti-CD3-FITC antibody was purchased from Tonbo Biosciences (San Diego, CA, USA). Anti-MICA/B-PE, anti-CD155-PE, anti-Nectin2-FITC, anti-UL16-binding protein (ULBP)-1, anti-ULBP-2, anti-ULBP-3, and anti-CD155 antibodies were purchased from R&D Systems (Minneapolis, MN, USA). Anti-PD-L1-PE was purchased from Immunotech Beckman Coulter (Brea, CA, USA). Anti-TIGIT-PE and anti-PD-1-PE antibodies were purchased from Biolegend (San Diego, CA, USA). Anti-actin antibody was purchased from Sigma-Aldrich (St. Louis, MO, USA). Purified anti-CD155 antibody for the functional blocking of CD155 was purchased from Biolegend. A Mini Dialysis Kit (GE Healthcare, Tokyo, Japan) was used for antibody purification in order to remove sodium azide as described previously (33). The anti-CD155 antibody for immunohistochemistry was purchased from Cell Signaling (Tokyo, Japan).

Cell culture. HKe3, HKe3-wtKRAS, HKe3-mtKRAS, and HKe3-CD155 cells were maintained as described previously (30, 31). Human peripheral blood mononuclear cells (PBMCs) were obtained from the blood of healthy volunteers who provided written informed consent. PBMCs were maintained in RPMI-1640 medium (Nacalai Tesque, Kyoto, Japan) supplemented with 5% human serum, 2000 units/ml penicillin (Meijiseika, Tokyo, Japan), and 10 μg/ml streptomycin (Meijiseika) as previously described (34).

3DF cell culture. Cells were seeded in round-bottomed 96-well plates with ultralow attachment surfaces (Corning Inc., Corning, NY, USA). Cells were cultured in a CO2 incubator as described previously (30, 35, 36).

Flow cytometry. Cancer cells in 2D culture were detached from culture plates using Accutase Solution (Promo Cell, Heidelberg, Germany). In 3DF culture, cancer spheroids were harvested by centrifuging 96-well plates for 5 min at 200 × g and then separated into individual cells using Accutase Solution. PBMCs, CAK, and cancer cells were washed twice in cold phosphate-buffered saline (PBS), suspended in FACS buffer (5% bovine serum albumin and 0.05% sodium azide in PBS), and incubated with fluorophore-conjugated antibodies in FACS buffer for 60 min at 4°C. Fluorescence was detected using an FC500 flow cytometer (Beckman Coulter) and expressed as relative median fluorescence intensity (MFI) or percentage above baseline as determined with FlowJo software (Tree Star, Inc., San Carlos, CA, USA).

Western blotting. Cells were lysed in RIPA buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and protease inhibitor cocktail (Roche, Basel, Switzerland)) and were subjected to immunoblotting as described previously (37). Quantitative analysis of immunoblots was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Patients and tumor samples. Formalin-fixed, paraffin-embedded tissues were obtained from eight patients with CRC who underwent surgery at Fukuoka University Hospital. The study protocol was approved by the Institutional Review Board of Fukuoka University (No. U19-08-006). KRAS mutations in unstained paraffin sections containing cancer cells were detected at the laboratory of SRL Inc. (Fukuoka, Japan) using polymerase chain reaction reverse sequence-specific oligonucleotide (PCR-rSSO). A summary of patients' characteristics is provided in Table I. All participants provided informed written consent. The research was conducted per the Declaration of Helsinki and Title 45, US Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001.

Figure 1.
Figure 1.

mtKRAS promotes the infiltration of cytokine-activated killer (CAK) cells into spheroids. Upper panels represent images of spheroids of HKe3 wild-type (wt) KRAS (left) and Hke3 mutant (mt) KRAS (right) co-cultured with peripheral blood mononuclear cells (PBMCs) or CAK cells. Scale bar, 500 μm. Enlarged images of areas enclosed by black lines in the upper panels are shown for the middle (*: the superficial part of spheroids) and lower panels (**: the central part of spheroids). The middle and lower panels represent merged images for both calcein AM and normal light signals. Scale bar, 50 μm.

Immunohistochemical analysis. Colorectal cancer tissues were fixed in 10% formalin, processed into paraffin blocks, sectioned (4-μm thickness), deparaffinized, and hydrated in descending alcohol dilutions. Sections were heated in 10 mM ethylenediaminetetraacetic acid (EDTA) buffer (pH 9.0) in a microwave (800 W) for 20 min to retrieve epitopes before staining and were then immersed in 3% hydrogen peroxide in water for 10 min at room temperature (RT) to block endogenous peroxidase activity. Sections were subsequently washed in Tris-buffered saline (TBS) and incubated with anti-human CD155 antibody (1:200) overnight at 4°C. Sections were washed again in TBS and incubated for 1 h at RT with EnVision reagent conjugated horseradish peroxidase (Dako, Carpinteria, CA, USA). Immunoreactive proteins were visualized with 3,3’-diamino-benzidine (Dako), followed by counterstaining with Mayer's hematoxylin for 1 min. Specimens were viewed using a BZ-X710 All-in-One Fluorescence Microscope (Keyence, Osaka, Japan).

Generation of cytokine-activated killer cells. PBMCs were activated in KBM551 medium (Kohjin Bio, Saitama, Japan) supplemented with 5% human serum, 2000 U/ml penicillin, 10 μg/ml streptomycin, 2000 U/ml recombinant human interleukin-2 (IL-2), and 0.5% albumin (Nihon Pharmaceutical Co., Ltd., Tokyo, Japan) in T-75 flasks coated with 2 μg/ml anti-CD3 monoclonal antibody (OKT3, Janssen Pharmaceutical K.K., Tokyo, Japan). After 5 days of activation, these cells were collected as CAK cells.

Infiltration of spheroids by CAK cells. HKe3-mtKRAS cells were seeded at 1000 cells/well into round-bottomed 96-well plates with an ultralow attachment surface for 3DF culture. Cells were cultured for 4 days in a CO2 incubator as described previously (36). CAK cells were stained with calcein AM (Dojindo, Kumamoto, Japan) according to the manufacturer's instructions. About 2,000 cells/well calcein AM-stained CAK cells were then added into the culture medium of spheroids. After 48 h, HKe3-mtKRAS spheroids were collected, and any CAK cells that had infiltrated into the spheroids were imaged using a TCS-SP5 laser scanning confocal microscope (Leica, Wetzlar, Germany).

Immunofluorescence labeling. Immunofluorescence labeling was performed overnight at 4°C using cleaved caspase-3 (Cell Signaling Technology, Beverly, MA, USA) as previously described (35). DAPI and CytoPainter Phalloidin-iFluor 555 Reagent (Abcam, Cambridge, UK) were used for the counterstaining of spheroid surfaces.

Figure 2.
Figure 2.

Increased expression of inhibitory natural killer (NK) receptors on the surface of cytokine-activated killer (CAK) cells. Activation of inhibitory NK receptors on the surface of peripheral blood mononuclear cells (PBMCs) or CAK cells. Flow cytometric profiles of CD3 (x-axis) and PD-1 (right panel) or TIGIT (y-axis) (left panel) on PBMCs or CAK cells. The numbers indicate the percentage of cells in each gate±SD from three biological replicates.

Co-culture of cancer and CAK cells. Cancer cells (HKe3-wtKRAS, 3000 per well; HKe3-mtKRAS, 1000 per well) were seeded in round-bottomed 96-well plates with ultralow attachment surfaces for 3DF culture. Cancer cells were cultured for 4 days in a CO2 incubator as described previously (30, 36). Co-culture of these cells with CAK cells (cancer/CAK cell ratio of 1:40) was then initiated, and this time point was considered day 0. Images of cells were taken using a BIOREVO BZ9000 microscope (Keyence), and spheroid area was measured using a BZ Analyzer (Keyence) as described previously (35, 38). Growth rates of tumor spheroids were calculated based on the changes in spheroid area on days 0, 3, and 7.

Detection of apoptotic cells in spheroids. Apoptotic cells were stained on day 7 using a Magic Red Caspase 3&7 Assay Kit (ImmunoChemistry Technologies, LLC, Bloomington, MN, USA) according to the manufacturer's instructions. Cells were imaged using a TCS-SP5 laser scanning confocal microscope (Leica).

Statistical analyses in cell culture experiments. Statistical analyses were performed using unpaired two-tailed Student's t-tests. All p-values less than 0.05 were considered statistically significant.

Results

mtKRAS promotes the infiltration of CAK cells into spheroids. To confirm that PBMCs and CAK cells target CRC spheroids with or without mtKRAS, PBMCs and CAK cells were stained by green fluorescence and subsequently co-cultured with HKe3-wtKRAS spheroids or HKe3-mtKRAS spheroids. PBMCs and CAK cells weakly were found to infiltrate HKe3-wtKRAS spheroids (Figure 1). In contrast, PBMCs and CAK cells readily infiltrated into the shallow layer of HKe3-mtKRAS spheroids (Figure 1). Notably, CAK cells also infiltrated into the deep layer of HKe3-mtKRAS spheroids, suggesting a role of mtKRAS in immune cell infiltration.

Increased expression of inhibitory NK receptors on the surface of CAK cells. CAK cells have been previously shown to express NK-activating receptors including DNAM-1 and NKG2D (19). Flow cytometry was used to assess the expression levels of inhibitory NK receptors on CAK cells. The percentages of CD3+PD-1+ and CD3+TIGIT+ cells in the CAK cell population were 6.6-fold and 5.1-fold higher than that in PBMCs, respectively (Figure 2), suggesting that PD-1 and TIGIT play key roles during the transition from PBMCs to CAK cells.

mtKRAS up-regulates the surface expression of CD155 in CRC spheroids. Flow cytometry using cells dispersed from 3DF culture was used to examine the expression levels of ligands of NK receptors, including DNAM-1, NKG2D, PD-L1, and TIGIT, in HKe3-wtKRAS or HKe3-mtKRAS (Figure 1a, b). No significant differences between mean fluorescence intensities (MFI) of ligands between wt and mt spheroids were observed (Figure 3a). However, surface expression levels of CD155 (DNAM-1 and TIGIT ligands) in both HKe3-wtKRAS and HKe3-mtKRAS cells in 3DF culture were higher than the levels in 2D culture. Further, MFI of CD155 in HKe3-mtKRAS spheroids was 1.57-fold higher than MFI in HKe3-wtKRAS spheroids (Figure 3b; *p<0.05), suggesting that mtKRAS is involved in the up-regulation of CD155. No significant differences in CD155 protein levels were observed in lysates between HKe3-wtKRAS and HKe3-mtKRAS cells from 3DF and 2D culture (Figure 3c). These results suggest that surface expression of CD155 in CRC spheroids is up-regulated by mtKRAS, although the total levels of CD155 protein remain unchanged.

Surface expression of CD155 in CRC tissues with mtKRAS. Immunohistochemistry was used to examine the differences in expression levels of CD155 between CRC tissues with or without mtKRAS in vivo. Two-thirds of samples with wtKRAS show weak membrane staining for CD155 in CRC tissues, similar to staining observed in adjacent normal colorectal tissues (Table I and Figure 4, upper panel). Sixty percent of samples with mtKRAS showed more prominent membrane staining for CD155 in CRC tissue than in adjacent normal colorectal tissues (Table I and Figure 4, lower panel). Together with the results shown in Figure 3, these findings suggest that mtKRAS up-regulates the surface expression of CD155 in CRC tissues.

Figure 3.
Figure 3.

Mutant (mt) KRAS up-regulates the surface expression of CD155 on spheroids. (a) The surface expression of CD112, MICA/B, ULBP1, ULBP2, ULBP3, and PD-L1 on HKe3, HKe3 wild-type (wt) and mutant (mt) spheroids. FACS profiles of ligands of natural killer receptors on HKe3-wtKRAS spheroids and HKe3-mtKRAS spheroids. The x-axis is fluorescence intensity, and the y-axis is the number of cells. The white histograms show unstained control cells, and the black histograms show cells stained with specific antibodies. Histograms are representative of three biological replicates, and the insert number on each histogram indicates MFI±SD. (b) Surface expression of CD155 on HKe3-wtKRAS cells and HKe3-mtKRAS cells in 2D or 3DF culture on day 4. FACS profiles of CD155 on HKe3-wtKRAS spheroids and HKe3-mtKRAS spheroids (left panel). The x-axis is the fluorescence intensity, and the y-axis is the number of cells. The white histograms show the unstained control cells and the black histograms show cells stained with anti-CD155 antibody. Histograms are representative of three biological replicates (left panel), and the MFIs±SD of CD155 in HKe3-wtKRAS cells and HKe3-mtKRAS cells in 2D and 3DF cultures are shown in the right panel. *p<0.05, n.s.: not significant. (c) The expression levels of CD155 protein in HKe3 cells, HKe3-wtKRAS cells, and HKe3-mtKRAS cells in 2D or 3DF culture. β-actin was used as a loading control. Levels of proteins were quantified by densitometry and normalized to actin levels. Values are relative ratios to levels in HKe3 spheroids. Data are representative of three biological replicates.

View this table:
Table I.

Clinicopathological details of patients.

Figure 4.
Figure 4.

The surface expression of CD155 is up-regulated in colorectal cancer (CRC) tissues with mutant (mt) KRAS. The expression levels of CD155 protein in CRC tissues with wild-type KRAS (upper left panel), mtKRAS (lower left panel), and paired adjacent normal tissues (right panel) were determined by immunohistochemistry. Scale bar, 50 μm.

Expression of CD155 at the invasion front of CRC tissues with mtKRAS is associated with the infiltration of CD3-positive T lymphocytes. Prominent expression of CD155 was hypothesized to be associated with the infiltration of immune cells. Immunohistochemistry of CD3 using CRC tissues (Table I) was performed to test this hypothesis. Serial sections of paraffin-embedded tissues from CRC patients with wtKRAS or mtKRAS were stained with HE (upper panel) and for CD155 (middle panel) and CD3 (lower panel) by immunohistochemistry. The numbers of tumor-infiltrating lymphocytes were counted in 13 randomly selected invasion fronts. Seven lesions showed weak CD155 expression (Figure 5a, left panel and Figure 5b), and six lesions showed prominent CD155 expression (Figure 5a, right panel and Figure 5b). A majority of invasion fronts (83.3%) with prominent CD155 expression showed increased numbers of infiltrating CD3-positive T lymphocytes (Figure 5a, right panel and Figure 5b). Notably, among lesions with prominent CD155 staining, all lesions with high infiltration numbers were identified as CRC with mtKRAS (Figure 5a, right panel and Figure 5b). Results suggest that both prominent CD155 expression and mtKRAS signals are important for infiltration by lymphocytes.

Figure 5.
Figure 5.

Prominent expression of CD155 at the invasion fronts of colorectal cancer (CRC) tissues with mutant (mt) KRAS is associated with the infiltration of CD3-positive T lymphocytes. (a) Upper panels are representative images of HE staining. The expression levels of CD155 protein (middle panel) and CD3 protein (lower panel) in CRC tissues with wild-type (wt) KRAS (left panel) and mtKRAS (right panel) were determined by immunohistochemistry. Scale bar, 100μm. (b) The circle represents the individual invasion front with wtKRAS (green) or mtKRAS (pink). Y-axis is the number of CD3-positive cells at the invasion front.

CAK cells under CD155 and PD-1 blockade suppress growth of HKe3-mtKRAS spheroids in a 3DF co-culture system via induction of luminal apoptosis. Time-dependent changes in spheroid area in 3DF co-cultures were used to assess cytotoxic capacity of CAK cells under a CD155 and PD-1 blockade for HKe3-mtKRAS in vitro. A CD155 function blocking antibody was used as described previously (33). Spheroid areas treated with anti-CD155 antibody were 1.7-fold smaller than controls (Figure 6a; *p<0.05), suggesting growth suppression by blocking CD155-associated signals. Direct cytotoxicity of CAK cells was assessed by co-culturing with HKe3-mtKRAS spheroids. No significant differences in spheroid area were observed between HKe3-mtKRAS spheroids treated with CAK cells alone and the control (Figure 6a). CAK cell cytotoxicity may be suppressed by an immune checkpoint. However, spheroid areas in co-culture with CAK cells with anti-CD155 antibody were 3.2-fold smaller compared to those co-cultured with CAK cells alone (Figure 6a; **p<0.01) and 1.8-fold smaller than spheroids treated with CD155 antibody alone. CD155 blockade may release the cytotoxic capabilities of CAK cells in addition to suppressing spheroid growth.

Figure 6.
Figure 6.

Cytokine-activated killer (CAK) cells under CD155 and PD-1 blockade suppress the growth of HKe3 mutant (mt) KRAS spheroids in a 3DF co-culture system via the induction of luminal apoptosis. (a) Representative images of HKe3-mtKRAS spheroids from three biological replicates (left panel). Scale bar, 100 μm. The right panel is the relative areas of HKe3-mtKRAS spheroids incubated with CAK cells, nivolumab-treated CAK cells, anti-CD155 antibody, CAK cells with anti-CD155 antibody, nivolumab-treated CAK cells, or nivolumab-treated CAK cells with anti-CD155 antibody in 3DF culture. Mean±SD from three technical replicates are shown. *p<0.05. **p<0.001. n.s.: not significant. (b) Representative signals for cleaved caspase-3 in HKe3-mtKRAS spheroids from three biological replicates. Enlarged images of the areas enclosed by white lines in the left panels are shown. Cleaved caspase-3, green; actin, red; DAPI, blue. Scale bar, 100 μm (low-magnification images) or 20 μm (high-magnification images).

Similar results were observed for PD-1 blockade. PBMCs were treated with nivolumab (a PD-1 inhibitor) during CAK cell activation; nivolumab-treated CAK cells were subsequently co-cultured with HKe3-mtKRAS spheroids (Figure 6a). The spheroid areas in cultures with nivolumab-treated CAK cells were 1.5-fold smaller compared to spheroids cultured with untreated CAK cells (Figure 6a). PD-1 blockade may also release the cytotoxic capability of CAK cells.

Finally, spheroid areas in co-culture with nivolumab-treated CAK cells with anti-CD155 antibody were 1.5-fold smaller than that of spheroids co-cultured with CAK cells with anti-CD155 antibody (Figure 6a; *p<0.05). CAK cells subjected to a combination blockade of CD155 and PD-1 had greater efficacy against CRC spheroids containing mtKRAS than CAK cells blockaded against either target alone. Overall, mtKRAS appears to protect cells from the attack by CAK cells.

Apoptotic activity was assessed to address whether the influence of CD155 blockade extends to apoptosis. HKe3-mtKRAS in 3DF co-culture for 7 days was evaluated for cleaved caspase-3/caspase-7 using confocal microscopy. Luminal space was distinguished by counterstaining surfaces of spheroids using DAPI and phalloidin. Luminal apoptosis was detected in spheroids cultured with CAK cells and with anti-CD155 antibody (Figure 6b). Apoptosis was further augmented in spheroids cultured with nivolumab-treated CAK cells with anti-CD155 antibody.

Discussion

Previous studies show that CD155 expression is up-regulated in many human malignancies, including CRC, and is correlated with tumor progression and unfavorable prognosis (39-42). Furthermore, oncogenic Ras up-regulates CD155 expression via MEK/ERK signaling in mouse NIH3T3 cells (43), suggesting that mtKRAS transcriptionally controls CD155 expression in CRC expressing mtKRAS. In this study, mtKRAS did not increase the total amount of CD155 protein but increased the expression of CD155 protein on the surface of CRC spheroids in 3DF culture (Figure 3b, c). In clinical samples, mtKRAS was associated with increased levels of CD155 on cell membranes in CRC tissues expressing mtKRAS (Figure 4). Further, the surface expression levels of CD155 protein in both HKe3-wtKRAS and HKe3-mtKRAS spheroids in 3DF culture were much higher than in 2D culture (Figure 3b). These results suggest that the mtKRAS-CD155 axis plays a key role in the 3D microenvironment. Previously, mtKRAS was shown to inhibit cellular polarity and luminal apoptosis in 3D culture (35), suggesting that the surface expression of various proteins on spheroids is altered under these conditions. Another recent study shows that mtKRAS affects the cellular sorting system of CRC cells (44), raising the possibility that mtKRAS also controls sorting of CD155.

Many studies have shown that extensive NK infiltration is associated with advanced disease and may even facilitate cancer development (45). The exact role of the tumor-infiltrating NK cells and the correlation between their presence and poor prognosis remains still unclear. An increased number of CD3+PD1+TIGIT+ CAK cells that infiltrate into spheroids from CRC cells with mtKRAS was observed (Figure 1). Similarly, CD3+ T cells were found to infiltrate into invasion fronts of CRC tissues with mtKRAS (Figure 5). mtKRAS may promote the infiltration of lymphocytes in CRC, and the identification of tumor-infiltrating lymphocytes at the invasion fronts of CRC samples may help determine the severity of prognosis.

Single CD155 blockade suppresses the area of spheroids and increases signals of cleaved caspase-3 (Figure 6), and the CD155 antibody may directly induce apoptosis. Furthermore, both anti-CD155 antibody and nivolumab similarly unleash the cytotoxic capabilities of CAK cells and coordinately promote antitumor immunity in the co-culture system (Figure 6). CD155–TIGIT or PD-L1–PD-1 interactions may act as an immune checkpoint inside spheroids. In cytokine-induced killer (CIK) cells, activated by CAK-cell medium (including IL-2 and CD3 antibodies) with interferon γ, treatments that block PD-1 or TIGIT are reportedly effective at increasing the cytotoxic action of CIK cells to targeted tumor cells (46, 47). Both blockades may act similarly as immune checkpoints for CIK/CAK cells. TIGIT has a stronger affinity for CD155 than DNAM1, and the CD155–TIGIT interaction is recognized as a strong immune inhibitory system in NKT and NK cells (48).

Consistent with the present study, where dual blockade of CD155 and PD-1 suppresses growth of HKe3-mtKRAS spheroids (Figure 6), dual blockade of TIGIT and PD-1 suppresses tumor growth in a murine glioblastoma model (49). Inhibiting both CD155–TIGIT and PD-L1–PD-1 pathways is thus more effective than inhibiting CD155–TIGIT alone. When comparing CD155 and TIGIT blockades, it appears that TIGIT blockade targets only the extrinsic signal due to predominant expression of TIGIT on immune cells (50), whereas CD155 blockade, targets both intrinsic and extrinsic signals and thus could be expected to be more efficient than a TIGIT blockade for CAK/CIK-treated patients with CRC containing mtKRAS.

In conclusion, the co-culture system mimicking microenvironments allowed a demonstration that mtKRAS modulates the surface expression of CD155 and that the infiltration of CAK cells may directly induce cancer cell proliferation. Patient samples show similar expression patterns and infiltration of CD3-positive cells. mtKRAS suppresses antitumor immunity by enhancing TIGIT–CD155 interactions. Thus, CD155 blockade may be useful, in the future, for treating cancers that express mtKRAS.

Acknowledgements

The Authors would like to thank Takami Danno, Yuriko Isoyama, Miki Onitsuka, and Yumiko Hirose for their technical assistance. This work was supported by Grant-in-Aid for Scientific Research (C) (KAKENHI, Grant Number 15K06847, 18K07215) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan and the Fukuoka Foundation for Sound Health Cancer Research Fund.

Footnotes

  • Authors' Contributions

    KN, TM, TS, SS and TT designed the study. KN, SI, MU, TI, AS and TT carried out in vitro experiments and drafted the manuscript. TK, MA, SN, YY, SH and KN carried out immunohistochemical analysis. KN, MA, SN, KN, TS, SS and TT, participated in the data interpretation. KN, AS, SS, and TT prepared the final manuscript. As the principal investigator, TT supervised the study. All Authors read and approved the final manuscript.

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors declare that they have no competing interests.

  • Received May 23, 2020.
  • Revision received June 17, 2020.
  • Accepted June 18, 2020.

References

  1. ↵
    1. Garcia-Rostan G,
    2. Zhao H,
    3. Camp RL,
    4. Pollan M,
    5. Herrero A,
    6. Pardo J,
    7. Wu R,
    8. Carcangiu ML,
    9. Costa J,
    10. Tallini G
    : Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21(17): 3226-3235, 2003. PMID: 12947056. DOI: 10.1200/jco.2003.10.130
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Castagnola P,
    2. Giaretti W
    : Mutant kras, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta 1756(2): 115-125, 2005. PMID: 16112461. DOI: 10.1016/j.bbcan.2005.06.003
    OpenUrlPubMed
  3. ↵
    1. Imamura Y,
    2. Morikawa T,
    3. Liao X,
    4. Lochhead P,
    5. Kuchiba A,
    6. Yamauchi M,
    7. Qian ZR,
    8. Nishihara R,
    9. Meyerhardt JA,
    10. Haigis KM,
    11. Fuchs CS,
    12. Ogino S
    : Specific mutations in kras codons 12 and 13, and patient prognosis in 1075 braf wild-type colorectal cancers. Clin Cancer Res 18(17): 4753-4763, 2012. PMID: 22753589. DOI: 10.1158/1078-0432.ccr-11-3210
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Hiraoka K,
    2. Inoue T,
    3. Taylor RD,
    4. Watanabe T,
    5. Koshikawa N,
    6. Yoda H,
    7. Shinohara K,
    8. Takatori A,
    9. Sugimoto H,
    10. Maru Y,
    11. Denda T,
    12. Fujiwara K,
    13. Balmain A,
    14. Ozaki T,
    15. Bando T,
    16. Sugiyama H,
    17. Nagase H
    : Inhibition of kras codon 12 mutants using a novel DNA-alkylating pyrrole-imidazole polyamide conjugate. Nat Commun 6: 6706, 2015. PMID: 25913614. DOI: 10.1038/ncomms7706
    OpenUrlCrossRefPubMed
  5. ↵
    1. Karapetis CS,
    2. Khambata-Ford S,
    3. Jonker DJ,
    4. O'Callaghan CJ,
    5. Tu D,
    6. Tebbutt NC,
    7. Simes RJ,
    8. Chalchal H,
    9. Shapiro JD,
    10. Robitaille S,
    11. Price TJ,
    12. Shepherd L,
    13. Au HJ,
    14. Langer C,
    15. Moore MJ,
    16. Zalcberg JR
    : K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17): 1757-1765, 2008. PMID: 18946061. DOI: 10.1056/NEJMoa0804385
    OpenUrlCrossRefPubMed
  6. ↵
    1. Stojanovic A,
    2. Cerwenka A
    : Checkpoint inhibition: Nk cells enter the scene. Nat Immunol 19(7): 650-652, 2018. PMID: 29915295. DOI: 10.1038/s41590-018-0142-y
    OpenUrl
  7. ↵
    1. Patel SA,
    2. Longacre TA,
    3. Ladabaum U,
    4. Lebensohn A,
    5. Lin AY,
    6. Haraldsdottir S
    : Tumor molecular testing guides anti-pd-1 therapy and provides evidence for pathogenicity of mismatch repair variants. Oncologist 23(12): 1395-1400, 2018. PMID: 30072391. DOI: 10.1634/theoncologist.2018-0108
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Lu YC,
    2. Robbins PF
    : Cancer immunotherapy targeting neoantigens. Semin Immunol 28(1): 22-27, 2016. PMID: 26653770. DOI: 10.1016/j.smim.2015.11.002
    OpenUrl
  9. ↵
    1. Le DT,
    2. Durham JN,
    3. Smith KN,
    4. Wang H,
    5. Bartlett BR,
    6. Aulakh LK,
    7. Lu S,
    8. Kemberling H,
    9. Wilt C,
    10. Luber BS,
    11. Wong F,
    12. Azad NS,
    13. Rucki AA,
    14. Laheru D,
    15. Donehower R,
    16. Zaheer A,
    17. Fisher GA,
    18. Crocenzi TS,
    19. Lee JJ,
    20. Greten TF,
    21. Duffy AG,
    22. Ciombor KK,
    23. Eyring AD,
    24. Lam BH,
    25. Joe A,
    26. Kang SP,
    27. Holdhoff M,
    28. Danilova L,
    29. Cope L,
    30. Meyer C,
    31. Zhou S,
    32. Goldberg RM,
    33. Armstrong DK,
    34. Bever KM,
    35. Fader AN,
    36. Taube J,
    37. Housseau F,
    38. Spetzler D,
    39. Xiao N,
    40. Pardoll DM,
    41. Papadopoulos N,
    42. Kinzler KW,
    43. Eshleman JR,
    44. Vogelstein B,
    45. Anders RA,
    46. Diaz LA Jr..
    : Mismatch repair deficiency predicts response of solid tumors to pd-1 blockade. Science 357(6349): 409-413, 2017. PMID: 28596308. DOI: 10.1126/science.aan6733
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. El-Jawhari JJ,
    2. El-Sherbiny YM,
    3. Scott GB,
    4. Morgan RS,
    5. Prestwich R,
    6. Bowles PA,
    7. Blair GE,
    8. Tanaka T,
    9. Rabbitts TH,
    10. Meade JL,
    11. Cook GP
    : Blocking oncogenic ras enhances tumour cell surface mhc class i expression but does not alter susceptibility to cytotoxic lymphocytes. Mol Immunol 58(2): 160-168, 2014. PMID: 24365750. DOI: 10.1016/j.molimm.2013.11.020
    OpenUrlCrossRef
  11. ↵
    1. Charitou T,
    2. Srihari S,
    3. Lynn MA,
    4. Jarboui MA,
    5. Fasterius E,
    6. Moldovan M,
    7. Shirasawa S,
    8. Tsunoda T,
    9. Ueffing M,
    10. Xie J,
    11. Xin J,
    12. Wang X,
    13. Proud CG,
    14. Boldt K,
    15. Al-Khalili Szigyarto C,
    16. Kolch W,
    17. Lynn DJ
    : Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic kras(g13d) mutation. Br J Cancer 121(1): 37-50, 2019. PMID: 31133691. DOI: 10.1038/s41416-019-0477-7
    OpenUrl
  12. ↵
    1. Brooks J,
    2. Fleischmann-Mundt B,
    3. Woller N,
    4. Niemann J,
    5. Ribback S,
    6. Peters K,
    7. Demir IE,
    8. Armbrecht N,
    9. Ceyhan GO,
    10. Manns MP,
    11. Wirth TC,
    12. Kubicka S,
    13. Bernhardt G,
    14. Smyth MJ,
    15. Calvisi DF,
    16. Gurlevik E,
    17. Kuhnel F
    : Perioperative, spatiotemporally coordinated activation of t and nk cells prevents recurrence of pancreatic cancer. Cancer Res 78(2): 475-488, 2018. PMID: 29180478. DOI: 10.1158/0008-5472.can-17-2415
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. He XP,
    2. Song FJ,
    3. Liu XY,
    4. Wang Z,
    5. Li XX,
    6. Liu FY,
    7. Chen G,
    8. Jiang WP
    : The relationship between kras gene mutations and hla class I antigen downregulation in the metastasis of non-small cell lung cancer. J Int Med Res 41(5): 1473-1483, 2013. PMID: 23975858. DOI: 10.1177/0300060513489801
    OpenUrlCrossRefPubMed
  14. ↵
    1. Geller MA,
    2. Miller JS
    : Use of allogeneic nk cells for cancer immunotherapy. Immunotherapy 3(12): 1445-1459, 2011. PMID: 22091681. DOI: 10.2217/imt.11.131
    OpenUrlCrossRefPubMed
  15. ↵
    1. Kwon HJ,
    2. Kim N,
    3. Kim HS
    : Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Exp Mol Med 49(3): e311, 2017. PMID: 28360428. DOI: 10.1038/emm.2017.42
    OpenUrl
  16. ↵
    1. Roder JC,
    2. Haliotis T,
    3. Klein M,
    4. Korec S,
    5. Jett JR,
    6. Ortaldo J,
    7. Heberman RB,
    8. Katz P,
    9. Fauci AS
    : A new immunodeficiency disorder in humans involving nk cells. Nature 284(5756): 553-555, 1980. PMID: 6445041. DOI: 10.1038/284553a0
    OpenUrlCrossRefPubMed
  17. ↵
    1. Coca S,
    2. Perez-Piqueras J,
    3. Martinez D,
    4. Colmenarejo A,
    5. Saez MA,
    6. Vallejo C,
    7. Martos JA,
    8. Moreno M
    : The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79(12): 2320-2328, 1997. PMID: 9191519. DOI: 10.1002/(sici)1097-0142(19970615)79:12<2320::aid-cncr5>3.0.co;2-p
    OpenUrlCrossRefPubMed
  18. ↵
    1. Morisaki T,
    2. Hirano T,
    3. Koya N,
    4. Kiyota A,
    5. Tanaka H,
    6. Umebayashi M,
    7. Onishi H,
    8. Katano M
    : Nkg2d-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors. Anticancer Res 34(8): 4529-4538, 2014. PMID: 25075096.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Morisaki T,
    2. Onishi H,
    3. Katano M
    : Cancer immunotherapy using nkg2d and dnam-1 systems. Anticancer Res 32(6): 2241-2247, 2012. PMID: 22641658.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Martinet L,
    2. Smyth MJ
    : Balancing natural killer cell activation through paired receptors. Nat Rev Immunol 15(4): 243-254, 2015. PMID: 25743219. DOI: 10.1038/nri3799
    OpenUrlCrossRefPubMed
  21. ↵
    1. Cho H,
    2. Chung JY,
    3. Kim S,
    4. Braunschweig T,
    5. Kang TH,
    6. Kim J,
    7. Chung EJ,
    8. Hewitt SM,
    9. Kim JH
    : Mica/b and ulbp1 nkg2d ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer 14: 957, 2014. PMID: 25510288. DOI: 10.1186/1471-2407-14-957
    OpenUrlPubMed
  22. ↵
    1. Yu X,
    2. Harden K,
    3. Gonzalez LC,
    4. Francesco M,
    5. Chiang E,
    6. Irving B,
    7. Tom I,
    8. Ivelja S,
    9. Refino CJ,
    10. Clark H,
    11. Eaton D,
    12. Grogan JL
    : The surface protein tigit suppresses t cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 10(1): 48-57, 2009. PMID: 19011627. DOI: 10.1038/ni.1674
    OpenUrlCrossRefPubMed
  23. ↵
    1. Stanietsky N,
    2. Simic H,
    3. Arapovic J,
    4. Toporik A,
    5. Levy O,
    6. Novik A,
    7. Levine Z,
    8. Beiman M,
    9. Dassa L,
    10. Achdout H,
    11. Stern-Ginossar N,
    12. Tsukerman P,
    13. Jonjic S,
    14. Mandelboim O
    : The interaction of tigit with pvr and pvrl2 inhibits human nk cell cytotoxicity. Proc Natl Acad Sci USA 106(42): 17858-17863, 2009. PMID: 19815499. DOI: 10.1073/pnas.0903474106
    OpenUrlAbstract/FREE Full Text
    1. Stanietsky N,
    2. Rovis TL,
    3. Glasner A,
    4. Seidel E,
    5. Tsukerman P,
    6. Yamin R,
    7. Enk J,
    8. Jonjic S,
    9. Mandelboim O
    : Mouse tigit inhibits nk-cell cytotoxicity upon interaction with pvr. Eur J Immunol 43(8): 2138-2150, 2013. PMID: 23677581. DOI: 10.1002/eji.201243072
    OpenUrlCrossRefPubMed
  25. ↵
    1. Bottino C,
    2. Castriconi R,
    3. Pende D,
    4. Rivera P,
    5. Nanni M,
    6. Carnemolla B,
    7. Cantoni C,
    8. Grassi J,
    9. Marcenaro S,
    10. Reymond N,
    11. Vitale M,
    12. Moretta L,
    13. Lopez M,
    14. Moretta A
    : Identification of pvr (cd155) and nectin-2 (cd112) as cell surface ligands for the human dnam-1 (cd226) activating molecule. J Exp Med 198(4): 557-567, 2003. PMID: 12913096. DOI: 10.1084/jem.20030788
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Gao J,
    2. Zheng Q,
    3. Xin N,
    4. Wang W,
    5. Zhao C
    : Cd155, an onco-immunologic molecule in human tumors. Cancer Sci 108(10): 1934-1938, 2017. PMID: 28730595. DOI: 10.1111/cas.13324
    OpenUrlCrossRef
    1. Sun C,
    2. Mezzadra R,
    3. Schumacher TN
    : Regulation and function of the pd-l1 checkpoint. Immunity 48(3): 434-452, 2018. PMID: 29562194. DOI: 10.1016/j.immuni.2018.03.014
    OpenUrlCrossRefPubMed
  28. ↵
    1. Hosomi S,
    2. Grootjans J,
    3. Huang YH,
    4. Kaser A,
    5. Blumberg RS
    : New insights into the regulation of natural-killer group 2 member d (nkg2d) and nkg2d-ligands: Endoplasmic reticulum stress and cea-related cell adhesion molecule 1. Front Immunol 9: 1324, 2018. PMID: 29973929. DOI: 10.3389/fimmu.2018.01324
    OpenUrl
  29. ↵
    1. Dias Carvalho P,
    2. Guimaraes CF,
    3. Cardoso AP,
    4. Mendonca S,
    5. Costa AM,
    6. Oliveira MJ,
    7. Velho S
    : Kras oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment. Cancer Res 78(1): 7-14, 2018. PMID: 29263151. DOI: 10.1158/0008-5472.can-17-2084
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Tsunoda T,
    2. Ishikura S,
    3. Doi K,
    4. Iwaihara Y,
    5. Hidesima H,
    6. Luo H,
    7. Hirose Y,
    8. Shirasawa S
    : Establishment of a three-dimensional floating cell culture system for screening drugs targeting kras-mediated signaling molecules. Anticancer Res 35(8): 4453-4459, 2015. PMID: 26168486.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Shirasawa S,
    2. Furuse M,
    3. Yokoyama N,
    4. Sasazuki T
    : Altered growth of human colon cancer cell lines disrupted at activated ki-ras. Science 260(5104): 85-88, 1993. PMID: 8465203. DOI: 10.1126/science.8465203
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Chen YC,
    2. Ingram PN,
    3. Fouladdel S,
    4. McDermott SP,
    5. Azizi E,
    6. Wicha MS,
    7. Yoon E
    : High-throughput single-cell derived sphere formation for cancer stem-like cell identification and analysis. Sci Rep 6: 27301, 2016. PMID: 27292795. DOI: 10.1038/srep27301
    OpenUrl
  33. ↵
    1. Inozume T,
    2. Yaguchi T,
    3. Furuta J,
    4. Harada K,
    5. Kawakami Y,
    6. Shimada S
    : Melanoma cells control antimelanoma ctl responses via interaction between tigit and cd155 in the effector phase. J Invest Dermatol 136(1): 255-263, 2016. PMID: 26763445. DOI: 10.1038/jid.2015.404
    OpenUrlCrossRefPubMed
  34. ↵
    1. Morisaki T,
    2. Onishi H,
    3. Koya N,
    4. Kiyota A,
    5. Tanaka H,
    6. Umebayashi M,
    7. Ogino T,
    8. Nagamatsu I,
    9. Katano M
    : Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the nkg2d-mica/b system. Anticancer Res 31(7): 2505-2510, 2011. PMID: 21873167.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Tsunoda T,
    2. Takashima Y,
    3. Fujimoto T,
    4. Koyanagi M,
    5. Yoshida Y,
    6. Doi K,
    7. Tanaka Y,
    8. Kuroki M,
    9. Sasazuki T,
    10. Shirasawa S
    : Three-dimensionally specific inhibition of DNA repair-related genes by activated kras in colon crypt model. Neoplasia 12(5): 397-404, 2010. PMID: 20454511. DOI: 10.1593/neo.10170
    OpenUrlPubMed
  36. ↵
    1. Nishi K,
    2. Luo H,
    3. Ishikura S,
    4. Doi K,
    5. Iwaihara Y,
    6. Wills L,
    7. Baillie GS,
    8. Sakata T,
    9. Shirasawa S,
    10. Tsunoda T
    : Apremilast induces apoptosis of human colorectal cancer cells with mutant kras. Anticancer Res 37(7): 3833-3839, 2017. PMID: 28668883. DOI: 10.21873/anticanres.11762
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Ota T,
    2. Doi K,
    3. Fujimoto T,
    4. Tanaka Y,
    5. Ogawa M,
    6. Matsuzaki H,
    7. Kuroki M,
    8. Miyamoto S,
    9. Shirasawa S,
    10. Tsunoda T
    : Kras up-regulates the expression of mir-181a, mir-200c and mir-210 in a three-dimensional-specific manner in dld-1 colorectal cancer cells. Anticancer Res 32(6): 2271-2275, 2012. PMID: 22641662.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Tsunoda T,
    2. Ota T,
    3. Fujimoto T,
    4. Doi K,
    5. Tanaka Y,
    6. Yoshida Y,
    7. Ogawa M,
    8. Matsuzaki H,
    9. Hamabashiri M,
    10. Tyson DR,
    11. Kuroki M,
    12. Miyamoto S,
    13. Shirasawa S
    : Inhibition of phosphodiesterase-4 (pde4) activity triggers luminal apoptosis and akt dephosphorylation in a 3-d colonic-crypt model. Mol Cancer 11: 46, 2012. PMID: 22830422. DOI: 10.1186/1476-4598-11-46
    OpenUrlPubMed
  39. ↵
    1. Nakai R,
    2. Maniwa Y,
    3. Tanaka Y,
    4. Nishio W,
    5. Yoshimura M,
    6. Okita Y,
    7. Ohbayashi C,
    8. Satoh N,
    9. Ogita H,
    10. Takai Y,
    11. Hayashi Y
    : Overexpression of necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci 101(5): 1326-1330, 2010. PMID: 20331633. DOI: 10.1111/j.1349-7006.2010.01530.x
    OpenUrlCrossRefPubMed
    1. Bevelacqua V,
    2. Bevelacqua Y,
    3. Candido S,
    4. Skarmoutsou E,
    5. Amoroso A,
    6. Guarneri C,
    7. Strazzanti A,
    8. Gangemi P,
    9. Mazzarino MC,
    10. D'Amico F,
    11. McCubrey JA,
    12. Libra M,
    13. Malaponte G
    : Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget 3(8): 882-892, 2012. PMID: 22929570. DOI: 10.18632/oncotarget.594
    OpenUrlPubMed
    1. Nishiwada S,
    2. Sho M,
    3. Yasuda S,
    4. Shimada K,
    5. Yamato I,
    6. Akahori T,
    7. Kinoshita S,
    8. Nagai M,
    9. Konishi N,
    10. Nakajima Y
    : Clinical significance of cd155 expression in human pancreatic cancer. Anticancer Res 35(4): 2287-2297, 2015. PMID: 25862891.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Zheng Q,
    2. Wang B,
    3. Gao J,
    4. Xin N,
    5. Wang W,
    6. Song X,
    7. Shao Y,
    8. Zhao C
    : Cd155 knockdown promotes apoptosis via akt/bcl-2/bax in colon cancer cells. J Cell Mol Med 22(1): 131-140, 2018. PMID: 28816021. DOI: 10.1111/jcmm.13301
    OpenUrl
  43. ↵
    1. Hirota T,
    2. Irie K,
    3. Okamoto R,
    4. Ikeda W,
    5. Takai Y
    : Transcriptional activation of the mouse necl-5/tage4/pvr/cd155 gene by fibroblast growth factor or oncogenic ras through the raf-mek-erk-ap-1 pathway. Oncogene 24(13): 2229-2235, 2005. PMID: 28816021. DOI: 10.1038/sj.onc.1208409
    OpenUrlCrossRefPubMed
  44. ↵
    1. McKenzie AJ,
    2. Hoshino D,
    3. Hong NH,
    4. Cha DJ,
    5. Franklin JL,
    6. Coffey RJ,
    7. Patton JG,
    8. Weaver AM
    : Kras-mek signaling controls ago2 sorting into exosomes. Cell Rep 15(5): 978-987, 2016. PMID: 27117408. DOI: 10.1016/j.celrep.2016.03.085
    OpenUrlCrossRefPubMed
  45. ↵
    1. Levi I,
    2. Amsalem H,
    3. Nissan A,
    4. Darash-Yahana M,
    5. Peretz T,
    6. Mandelboim O,
    7. Rachmilewitz J
    : Characterization of tumor infiltrating natural killer cell subset. Oncotarget 6(15): 13835-13843, 2015. PMID: 26079948. DOI: 10.18632/oncotarget.3453
    OpenUrlCrossRefPubMed
  46. ↵
    1. Wang Z,
    2. Liu X,
    3. Till B,
    4. Sun M,
    5. Li X,
    6. Gao Q
    : Combination of cytokine-induced killer cells and programmed cell death-1 blockade works synergistically to enhance therapeutic efficacy in metastatic renal cell carcinoma and non-small cell lung cancer. Front Immunol 9: 1513, 2018. PMID: 30026742. DOI: 10.3389/fimmu.2018.01513
    OpenUrl
  47. ↵
    1. Zhang B,
    2. Zhao W,
    3. Li H,
    4. Chen Y,
    5. Tian H,
    6. Li L,
    7. Zhang L,
    8. Gao C,
    9. Zheng J
    : Immunoreceptor tigit inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with cd155. Cancer Immunol Immunother 65(3): 305-314, 2016. PMID: 26842126. DOI: 10.1007/s00262-016-1799-4
    OpenUrl
  48. ↵
    1. Mahnke K,
    2. Enk AH
    : Tigit-cd155 interactions in melanoma: A novel co-inhibitory pathway with potential for clinical intervention. J Invest Dermatol 136(1): 9-11, 2016. PMID: 26763417. DOI: 10.1016/j.jid.2015.10.048
    OpenUrl
  49. ↵
    1. Hung AL,
    2. Maxwell R,
    3. Theodros D,
    4. Belcaid Z,
    5. Mathios D,
    6. Luksik AS,
    7. Kim E,
    8. Wu A,
    9. Xia Y,
    10. Garzon-Muvdi T,
    11. Jackson C,
    12. Ye X,
    13. Tyler B,
    14. Selby M,
    15. Korman A,
    16. Barnhart B,
    17. Park SM,
    18. Youn JI,
    19. Chowdhury T,
    20. Park CK,
    21. Brem H,
    22. Pardoll DM,
    23. Lim M
    : Tigit and pd-1 dual checkpoint blockade enhances antitumor immunity and survival in gbm. Oncoimmunology 7(8): e1466769, 2018. PMID: 30221069. DOI: 10.1080/2162402x.2018.1466769
    OpenUrlCrossRefPubMed
  50. ↵
    1. Zhang Q,
    2. Bi J,
    3. Zheng X,
    4. Chen Y,
    5. Wang H,
    6. Wu W,
    7. Wang Z,
    8. Wu Q,
    9. Peng H,
    10. Wei H,
    11. Sun R,
    12. Tian Z
    : Blockade of the checkpoint receptor tigit prevents nk cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19(7): 723-732, 2018. PMID: 29915296. DOI: 10.1038/s41590-018-0132-0
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Mutant KRAS Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion
KENSUKE NISHI, SHUHEI ISHIKURA, MASAYO UMEBAYASHI, TAKASHI MORISAKI, TAKASHI INOZUME, TETSUSHI KINUGASA, MIKIKO AOKI, SATOSHI NIMURA, ANTHONY SWAIN, YOICHIRO YOSHIDA, SUGURU HASEGAWA, KAZUKI NABESHIMA, TOSHIFUMI SAKATA, SENJI SHIRASAWA, TOSHIYUKI TSUNODA
Anticancer Research Aug 2020, 40 (8) 4663-4674; DOI: 10.21873/anticanres.14465
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords